We are advancing a pipeline of multiple product candidates based on MeasoVir backbone: à faire un tableau: hematological cancers / solid tumors.
This technology, developed at the Institut Pasteur in Paris, has intellectual property protection up to 2033 with possible extensions that OncoVITA’s intellectual property portfolio is building upon.